Taiga Nishihori
Overview
Explore the profile of Taiga Nishihori including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
240
Citations
3400
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adoncecchi G, Kumar A, Mogili K, Faramand R, Liu H, Khimani F, et al.
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39858092
Background: Previous studies have shown that allogeneic peripheral blood stem cell transplantation (PBSCT) from an HLA haploidentical (haplo) donor followed by graft-versus-host disease (GVHD) prophylaxis with post-transplant cyclophosphamide (PTCy) results...
2.
Akhtar O, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, et al.
Blood Adv
. 2025 Jan;
PMID: 39786391
Idecabtagene vicleucel (ide-cel) is an anti-BCMA CAR-T cell therapy approved for patients with relapsed/refractory multiple myeloma (RRMM) after 2 prior lines of therapy. There is limited data on outcomes of...
3.
Freeman C, Noble J, Menges M, Villanueva R, Nakashima J, Figura N, et al.
Blood
. 2024 Dec;
PMID: 39652773
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a breakthrough treatment for relapsed and refractory multiple myeloma (RRMM). However, these products are complex to deliver and alternative options are...
4.
Sudalagunta P, Canevarolo R, Meads M, Silva M, Zhao X, Cubitt C, et al.
Cancer Res
. 2024 Oct;
85(2):378-398.
PMID: 39476082
Several therapeutic agents have been approved for treating multiple myeloma, a cancer of bone marrow-resident plasma cells. Predictive biomarkers for drug response could help guide clinical strategies to optimize outcomes....
5.
Wallis W, Gulbis A, Wang T, Lee C, Sharma A, Williams K, et al.
Bone Marrow Transplant
. 2024 Oct;
60(1):52-57.
PMID: 39420192
Bacterial bloodstream infections (BSI) can be a substantial contributor to complications of GVHD treatment. The aim of this study was to determine the risk for BSI from neutrophil engraftment through...
6.
Handley G, Yepes A, Eliassen E, Dominguez G, Pasikhova Y, Klinkova O, et al.
Open Forum Infect Dis
. 2024 Oct;
11(10):ofae564.
PMID: 39411216
Background: Human herpesvirus 6B (HHV-6B) frequently reactivates following allogeneic stem cell transplant (alloHCT). Consensus guidelines note that haploidentical alloHCT may represent a high-risk population for which there is little evidence;...
7.
Hoogland A, Barata A, Li X, Irizarry-Arroyo N, Jain M, Welniak T, et al.
Transplant Cell Ther
. 2024 Sep;
30(12):1219.e1-1219.e11.
PMID: 39306278
Chimeric antigen receptor (CAR) T-cell therapy has transformed survival outcomes in patients with relapsed and refractory large B-cell lymphoma (LBCL), but it is associated with a variety of side effects....
8.
Kahn J, Brazauskas R, Bo-Subait S, Buchbinder D, Hamilton B, Schoemans H, et al.
Lancet Child Adolesc Health
. 2024 Sep;
8(10):740-750.
PMID: 39217999
Background: Continued advances in haematopoietic cell transplantation (HCT) for children with non-malignant diseases (NMDs) have led to a growing population of survivors in whom late occurring toxic effects remain a...
9.
Bhatt V, Shostrom V, Choe H, Hamilton B, Gundabolu K, Maness L, et al.
J Clin Oncol
. 2024 Aug;
42(33):3977-3985.
PMID: 39151112
Purpose: Sclerotic chronic graft-versus-host disease (cGVHD) represents a highly morbid and refractory form of cGVHD, and novel therapies for sclerotic cGVHD are critically needed. This study aimed to determine the...
10.
Albanyan O, Elmariah H, Kalos D, Kim J, Faramand R, Sallman D, et al.
Transplant Cell Ther
. 2024 Aug;
30(11):1090.e1-1090.e10.
PMID: 39147136
Fludarabine (Flu) and melphalan (Mel) reduced-intensity conditioning is frequently used for allogenic hematopoietic cell transplant (allo-HCT) in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). However, there is...